patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_826183 | REC_0000801 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 11.6 | 66 | female | 1 | 17 | 3.8 | 2 | entrectinib 600 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:57.035308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292950 | REC_0000802 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13 | 60 | male | 1 | 12 | 4.7 | 1 | osimertinib 80 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:35:57.035551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722881 | REC_0000803 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.8 | 65 | male | 1 | 12 | 5 | 3 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.035793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644842 | REC_0000804 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 17.4 | 66 | female | 0 | 10 | 7 | 5 | entrectinib 600 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:57.036032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621134 | REC_0000805 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.9 | 79 | female | 2 | 13 | 6.9 | 8 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:57.036323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151292 | REC_0000806 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 5.9 | 64 | female | 1 | 11 | 6.8 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.036569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601013 | REC_0000807 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.2 | 72 | male | 1 | 17 | 5.3 | 1 | entrectinib 600 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:57.036912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617390 | REC_0000808 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.5 | 64 | male | 0 | 15 | 5.2 | 4 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.037161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201539 | REC_0000809 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.5 | 57 | female | 0 | 36 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:57.037402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592417 | REC_0000810 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 12.5 | 67 | female | 1 | 11 | 5.5 | 4 | alectinib 600 mg BID | 6.8 | false | MSI-H | 2026-03-15T05:35:57.037646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197392 | REC_0000811 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 35 | 6.3 | 62 | male | 0 | 38 | 4.3 | 1 | pembrolizumab 200 mg q3w | 25.4 | true | MSS | 2026-03-15T05:35:57.037892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912570 | REC_0000812 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 17.3 | 79 | female | 1 | 22 | 4.7 | 5 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.038135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762624 | REC_0000813 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.8 | 69 | male | 0 | 12 | 6.1 | 2 | entrectinib 600 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:57.038376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474953 | REC_0000814 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.8 | 75 | female | 2 | 8 | 3.9 | 3 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:35:57.038611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567763 | REC_0000815 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.5 | 80 | female | 2 | 0 | 6.4 | 3 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:57.038866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733230 | REC_0000816 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.6 | 70 | female | 3 | 21 | 6.4 | 6 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:57.039121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837978 | REC_0000817 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 12.2 | 76 | female | 1 | 18 | 4.3 | 2 | osimertinib 80 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:57.039381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204025 | REC_0000818 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9.6 | 64 | female | 1 | 17 | 3.5 | 7 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.039643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255864 | REC_0000819 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.1 | 63 | female | 1 | 23 | 4.5 | 5 | osimertinib 80 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:57.039918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193613 | REC_0000820 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7.3 | 65 | female | 0 | 16 | 6 | 4 | sotorasib 960 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:57.040369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109134 | REC_0000821 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8 | 69 | female | 0 | 23 | 5.8 | 6 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.040683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132975 | REC_0000822 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.2 | 53 | male | 0 | 8 | 4.4 | 1 | osimertinib 80 mg daily | 30.3 | false | MSI-H | 2026-03-15T05:35:57.040972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413165 | REC_0000823 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.8 | 82 | female | 1 | 26 | 5.9 | 5 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:57.041238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150904 | REC_0000824 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 14.3 | 75 | male | 1 | 13 | 6.2 | 2 | entrectinib 600 mg daily | 25 | true | MSI-H | 2026-03-15T05:35:57.041501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984173 | REC_0000825 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.5 | 62 | male | 1 | 16 | 5 | 3 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:57.041787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767127 | REC_0000826 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 15 | 71 | female | 1 | 17 | 5.9 | 6 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:57.042119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191918 | REC_0000827 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 11.2 | 77 | female | 1 | 16 | 5.4 | 5 | pembrolizumab 200 mg q3w | 8.5 | true | MSI-H | 2026-03-15T05:35:57.042407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706626 | REC_0000828 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.5 | 71 | female | 2 | 17 | 5.6 | 6 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:57.042683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483571 | REC_0000829 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 6.6 | 77 | male | 3 | 13 | 4.7 | 8 | pembrolizumab 200 mg q3w | 14.2 | true | MSS | 2026-03-15T05:35:57.042959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288606 | REC_0000830 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12.1 | 55 | male | 0 | 16 | 3.8 | 1 | sotorasib 960 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:57.043224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628403 | REC_0000831 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.9 | 67 | female | 1 | 43 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:35:57.043481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150723 | REC_0000832 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 13.8 | 72 | female | 1 | 9 | 5.1 | 8 | pembrolizumab 200 mg q3w | 7.9 | true | MSS | 2026-03-15T05:35:57.043735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614910 | REC_0000833 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.5 | 69 | female | 1 | 17 | 6.2 | 6 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.044161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712037 | REC_0000834 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 16.1 | 60 | male | 1 | 14 | 5.4 | 5 | osimertinib 80 mg daily | 14 | true | MSI-H | 2026-03-15T05:35:57.044485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466107 | REC_0000835 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.1 | 62 | male | 1 | 74 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:35:57.044758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221794 | REC_0000836 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.2 | 67 | female | 1 | 16 | 6.5 | 5 | osimertinib 80 mg daily | 5.3 | false | MSI-H | 2026-03-15T05:35:57.045020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246816 | REC_0000837 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.8 | 66 | male | 0 | 23 | 5.9 | 3 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.045327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926197 | REC_0000838 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 12.1 | 62 | female | 0 | 24 | 4.7 | 1 | alectinib 600 mg BID | 33.2 | true | MSI-H | 2026-03-15T05:35:57.045601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541099 | REC_0000839 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4.8 | 68 | female | 0 | 8 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:35:57.045868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506517 | REC_0000840 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.3 | 84 | male | 1 | 8 | 4 | 7 | osimertinib 80 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:57.046137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798374 | REC_0000841 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 8 | 46 | male | 0 | 7 | 6.1 | 2 | entrectinib 600 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:57.046402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302865 | REC_0000842 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.1 | 73 | female | 2 | 32 | 6.2 | 2 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:35:57.046679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190171 | REC_0000843 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 19.5 | 56 | female | 1 | 14 | 6.4 | 0 | sotorasib 960 mg daily | 28.4 | false | MSI-H | 2026-03-15T05:35:57.046967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744028 | REC_0000844 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 8.4 | 68 | female | 0 | 11 | 6.6 | 4 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:57.047226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279721 | REC_0000845 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 14 | 64 | female | 0 | 15 | 5.4 | 2 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:35:57.047489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343067 | REC_0000846 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 16.2 | 62 | female | 0 | 17 | 4.8 | 1 | alectinib 600 mg BID | 23 | true | MSS | 2026-03-15T05:35:57.047843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608188 | REC_0000847 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 14.4 | 71 | female | 1 | 10 | 5.7 | 2 | pembrolizumab 200 mg q3w | 20.6 | true | MSI-H | 2026-03-15T05:35:57.048138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843969 | REC_0000848 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 1.9 | 65 | male | 0 | 47 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:57.048403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732052 | REC_0000849 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 11.5 | 61 | male | 0 | 21 | 4.2 | 2 | alectinib 600 mg BID | 24 | false | MSS | 2026-03-15T05:35:57.048667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556010 | REC_0000850 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 6.8 | 78 | female | 2 | 25 | 4.1 | 8 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:57.048903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916334 | REC_0000851 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 17.4 | 58 | female | 1 | 10 | 6 | 8 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.049148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184513 | REC_0000852 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 16.1 | 70 | female | 2 | 9 | 6.5 | 7 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:57.049391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950732 | REC_0000853 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 7 | 71 | male | 1 | 41 | 5.9 | 8 | pembrolizumab 200 mg q3w | 6.7 | true | MSS | 2026-03-15T05:35:57.049631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255756 | REC_0000854 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 13.1 | 74 | male | 1 | 16 | 5.9 | 1 | pembrolizumab 200 mg q3w | 21.9 | true | MSI-H | 2026-03-15T05:35:57.049875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210195 | REC_0000855 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.7 | 64 | male | 1 | 12 | 6.7 | 2 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.050125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534598 | REC_0000856 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.2 | 78 | male | 1 | 28 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.050368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527328 | REC_0000857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.6 | 73 | male | 3 | 11 | 6.2 | 4 | entrectinib 600 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:57.050615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359871 | REC_0000858 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.3 | 52 | male | 0 | 15 | 4.5 | 3 | alectinib 600 mg BID | 11.5 | true | MSS | 2026-03-15T05:35:57.050861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137118 | REC_0000859 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6 | 69 | male | 1 | 47 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.7 | true | MSS | 2026-03-15T05:35:57.051220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922331 | REC_0000860 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.6 | 81 | female | 1 | 26 | 4.7 | 5 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.051467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350271 | REC_0000861 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.5 | 56 | male | 1 | 16 | 5.2 | 4 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:57.051716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656667 | REC_0000862 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 7.6 | 74 | female | 1 | 14 | 4.8 | 3 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:57.051958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281480 | REC_0000863 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 36 | 6.9 | 68 | female | 1 | 48 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.7 | false | MSS | 2026-03-15T05:35:57.052247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926724 | REC_0000864 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 7.7 | 58 | female | 1 | 14 | 4.8 | 4 | osimertinib 80 mg daily | 4.6 | false | MSS | 2026-03-15T05:35:57.052509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929084 | REC_0000865 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 7.7 | 70 | female | 2 | 36 | 7.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 41.6 | false | MSS | 2026-03-15T05:35:57.052755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428237 | REC_0000866 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.4 | 63 | female | 0 | 19 | 7 | 5 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.053002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643857 | REC_0000867 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 10.2 | 77 | female | 1 | 11 | 3.7 | 3 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:57.053248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189627 | REC_0000868 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10 | 59 | male | 1 | 11 | 4.2 | 6 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.053503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359286 | REC_0000869 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 5.1 | 69 | male | 1 | 46 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 4.7 | true | MSS | 2026-03-15T05:35:57.053747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914629 | REC_0000870 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 20.3 | 70 | female | 3 | 17 | 6.5 | 1 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:57.054005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581811 | REC_0000871 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 12.4 | 58 | male | 1 | 7 | 5.8 | 0 | osimertinib 80 mg daily | 43.8 | false | MSI-H | 2026-03-15T05:35:57.054270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144338 | REC_0000872 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 17 | 73 | female | 2 | 16 | 6.7 | 6 | alectinib 600 mg BID | 13.7 | true | MSI-H | 2026-03-15T05:35:57.054644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359966 | REC_0000873 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 6.2 | 76 | male | 1 | 10 | 7.2 | 8 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:57.054923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449769 | REC_0000874 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 14 | 12.7 | 84 | female | 2 | 17 | 4.7 | 2 | alectinib 600 mg BID | 17.8 | true | MSS | 2026-03-15T05:35:57.055194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698882 | REC_0000875 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.2 | 65 | female | 0 | 10 | 6 | 3 | sotorasib 960 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:57.055470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671920 | REC_0000876 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 21 | 62 | female | 1 | 19 | 5.9 | 5 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.055766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749492 | REC_0000877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 19.4 | 57 | female | 0 | 2 | 6.9 | 6 | osimertinib 80 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:57.056038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495748 | REC_0000878 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.9 | 65 | male | 0 | 2 | 6.9 | 4 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.056361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430034 | REC_0000879 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 4.7 | 75 | female | 1 | 60 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:57.056624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303514 | REC_0000880 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.6 | 62 | female | 1 | 18 | 2.1 | 2 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.056890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535423 | REC_0000881 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 18.5 | 71 | female | 1 | 13 | 6 | 7 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:35:57.057154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990034 | REC_0000882 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 33 | 8.2 | 57 | male | 0 | 11 | 6 | 0 | osimertinib 80 mg daily | 27.7 | true | MSS | 2026-03-15T05:35:57.057406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265251 | REC_0000883 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.5 | 59 | female | 0 | 45 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:57.057653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989392 | REC_0000884 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 6.2 | 54 | male | 0 | 12 | 4.7 | 8 | pembrolizumab 200 mg q3w | 7.6 | true | MSS | 2026-03-15T05:35:57.057901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142842 | REC_0000885 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 20.5 | 81 | female | 1 | 24 | 6.6 | 2 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.058266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259490 | REC_0000886 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 2.5 | 67 | female | 1 | 55 | 7.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.9 | false | MSS | 2026-03-15T05:35:57.058538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196417 | REC_0000887 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.5 | 57 | male | 0 | 17 | 7 | 6 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:57.058824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648307 | REC_0000888 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 11.2 | 68 | female | 0 | 15 | 6.8 | 9 | alectinib 600 mg BID | 14.5 | false | MSI-H | 2026-03-15T05:35:57.059160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758408 | REC_0000889 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.9 | 81 | male | 2 | 22 | 3.1 | 1 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:35:57.059485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951038 | REC_0000890 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.7 | 64 | female | 0 | 28 | 4.9 | 7 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:57.059785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984584 | REC_0000891 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 12.1 | 73 | female | 1 | 20 | 5.3 | 1 | alectinib 600 mg BID | 25.9 | false | MSS | 2026-03-15T05:35:57.060131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476429 | REC_0000892 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.6 | 64 | female | 0 | 21 | 5.5 | 1 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.060452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349432 | REC_0000893 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 12.9 | 56 | male | 1 | 17 | 5.9 | 1 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:57.060728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931895 | REC_0000894 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.9 | 64 | female | 1 | 28 | 4.5 | 7 | sotorasib 960 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.060978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452161 | REC_0000895 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.9 | 73 | female | 2 | 13 | 5 | 7 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:57.061217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959234 | REC_0000896 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 18.6 | 71 | female | 2 | 12 | 6.6 | 4 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.061457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412859 | REC_0000897 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.4 | 58 | female | 1 | 14 | 7.2 | 3 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:57.061700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536377 | REC_0000898 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.2 | 62 | female | 0 | 16 | 5.4 | 5 | alectinib 600 mg BID | 7.7 | false | MSS | 2026-03-15T05:35:57.062057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932211 | REC_0000899 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 18.4 | 65 | female | 1 | 11 | 3.8 | 7 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:57.062305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148650 | REC_0000900 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.9 | 79 | female | 1 | 66 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.9 | false | MSS | 2026-03-15T05:35:57.062547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.